Press reports of the acquisition of Dik Drug Co. remain uncorroborated by Cardinal
Although Cardinal Health protested vociferously when its Lakeland, FL, distribution center was suspended from distributing controlled substances by DEA in February, it has now settled with the agency. The penalty: a two-year suspension of controlled substances sales from the facility (operations for other distribution remain in place for the DC). Company officials indicated that it would continue to supply controlled substances for Florida, Georgia and South Carolina from its Jackson, MS, DC.
"This agreement allows us to put this matter behind us, and just as important, will clear the way for a more productive dialogue about how we and others in the health care and regulatory community can work together to prevent the abuse and misuse of prescription drugs," said George Barrett, chairman and CEO of Cardinal Health. The company is also obligated to improve anti-diversion processes.
Meanwhile, in a presentation at a Bank of America/Merrill Lynch conference recently, Cardinal CFO Jeff Henderson announced that the company’s 2010 acquisition of Zuellig Pharma China has progressed nicely; Cardinal has built two additional DCs, in Beijing and Shanghai, and says that it can now serve 250 million from its network of facilities there. Except for operations in Canada and Mexico, the others of the Big Three wholesalers do not have drug distribution businesses outside the US. What Henderson, or any other Cardinal executive, has not publicly confirmed is reports that it has acquired Dik Drug (Burr Ridge, IL), a privately held regional distributor. The news was broken by Adam Fein at DrugChannels.net, but as of May 15, Cardinal had still not issued a statement about it. Fein (a member of the Pharmaceutical Commerce Editorial Board) speculated that Dik’s annual revenues are around $2 billion, and noted that it is a part owner of Pharmacy First, a Pharmacy Services Administrative Organization (PSAO), which manages contracts between independent pharmacies and PBMs. Cardinal itself operates another PSAO, LeaderNet.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.